---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-042846"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-06-12T20:10:37+00:00"
generated_at: "2026-06-12T20:23:46.962656+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# CAMP4 stockholders approve 2024 Plan amendment; Board adopts 2026 Inducement Plan (500K shares) for new hires

## Summary
- Stockholders approved amendment to 2024 Equity Incentive Plan to include pre-funded warrants in evergreen share calculation.
- Board adopted 2026 Inducement Plan reserving 500,000 shares of common stock for inducement grants to new employees without stockholder approval.
- Annual meeting results: re-elected directors Holtzman, Stewart, Young; ratified Ernst & Young as auditor for FY2026.
- Plan amendment and inducement plan both effective as of June 10, 2026.

## SEC filing metadata
- accession: 0001628280-26-042846
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-06-12T20:10:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/camp-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-042846
- JSON: https://secwatch.observer/filing/0001628280-26-042846.json
- Plain text: https://secwatch.observer/filing/0001628280-26-042846.txt

## Key facts
- Shareholder Votes
  Camp4 Therapeutics Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 2. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 39,998,507 127 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm
- Shareholder Votes
  Camp4 Therapeutics Corp shareholders approved Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan at the 2026-06-10 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 3. The stockholders approved the amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 27,002,145 10,023,588 199,455 2,773,446
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm
- Shareholder Votes
  Camp4 Therapeutics Corp shareholders approved Election of Class II directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 1. The following nominees were elected as the Company’s Class II directors, each to serve for a three-year term until the 2029 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes: Nominees For Against Abstain Broker Non-Votes Steven Holtzman 29,233,042 7,992,146 — 2,773,446 Murray Stewart, DM FRCP 31,669,512 5,555,665 11 2,773,446 Richard Young, PhD 29,212,962 8,012,214 12 2,773,446
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.